Nephro-Urology Monthly

Published by: Kowsar

Chronic Hemodialysis Patients; Special Group for Hepatitis C Elimination Programs in Iran

Hamidreza Karimi-Sari 1 , 2 , 3 and Seyed Moayed Alavian 2 , 3 , *
Authors Information
1 Student Research Committee, Baqiyatallah University of Medical Sciences, Tehran, Iran
2 Baqiyatallah Research Center for Gastroenterology and Liver Diseases (BRCGL), Baqiyatallah University of Medical Sciences, Tehran, IR Iran
3 Middle East Liver Disease (MELD) Center, Tehran, Iran
Article information
  • Nephro-Urology Monthly: November 2017, 9 (6); e59941
  • Published Online: July 14, 2017
  • Article Type: Letter
  • Received: March 18, 2017
  • Accepted: May 6, 2017
  • DOI: 10.5812/numonthly.59941

To Cite: Karimi-Sari H, Alavian S M. Chronic Hemodialysis Patients; Special Group for Hepatitis C Elimination Programs in Iran, Nephro-Urol Mon. 2017 ; 9(6):e59941. doi: 10.5812/numonthly.59941.

Copyright © 2017, Nephro-Urology Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Footnotes
References
  • 1. Lancet T. Towards elimination of viral hepatitis by 2030. 2016;
  • 2. Hesamizadeh K, Sharafi H, Rezaee-Zavareh MS, Behnava B, Alavian SM. Next Steps Toward Eradication of Hepatitis C in the Era of Direct Acting Antivirals. Hepat Mon. 2016; 16(4): 37089[DOI][PubMed]
  • 3. Mirminachi B, Mohammadi Z, Merat S, Neishabouri A, Sharifi AH, Alavian SH. Update on the prevalence of hepatitis c virus infection among iranian general population: A systematic review and meta-analysis. Hepat Mon. 2017; 17(2)
  • 4. Makhlough A, Mahdavi M, Maleki I, Davoodi L, Mousavi T, Hasani-Mansoor SH, et al. The prevalence of hcv infection in hemodialysis population and compared elisa and pcr methods for detecting of hcv infection. Nephro-Urol Mon. 2017; [DOI]
  • 5. Abad S, Vega A, Hernandez E, Merida E, de Sequera P, Albalate M, et al. Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4. Am J Nephrol. 2017; 45(3): 267-72[DOI][PubMed]
  • 6. Saab S, A. Jimenez M , N. Bau S , Choi G, Durazo FA, M. El-Kabany M , et al. Use of Sofosbuvir-Based Treatment of Chronic Hepatitis C in Liver Transplant Recipients on Hemodialysis. J Clin Gastroenterol. 2017; 51(2): 167-73[DOI][PubMed]
  • 7. Alavian SM, Hajarizadeh B, Bagheri Lankarani K, Sharafi H, Ebrahimi Daryani N, Merat S, et al. Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline. Hepat Mon. 2016; 16(8): 40959[DOI][PubMed]
  • 8. Einollahi B, Alavian SM. Hepatitis C virus infection and kidney transplantation: a review for clinicians. Iran J Kidney Dis. 2010; 4(1): 1-8[PubMed]
  • 9. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ, Miller LG, Daar ES, Gjertson DW, et al. Hepatitis C virus and death risk in hemodialysis patients. J Am Soc Nephrol. 2007; 18(5): 1584-93[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments